INTRODUCTION
The protein product of the c-cbl proto-oncogene is involved in several signaling pathways and exerts a negative regulatory function on receptor and non-receptor tyrosine kinases (1) (2) (3) (4) (5) (6) (7) . Although the mechanism by which c-Cbl exerts this negative regulatory function remained unclear until recently, it is now apparent that in several instances c-Cbl works by promoting polyubiquitination of activated receptor protein tyrosine kinases (RTKs) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The domains of c-Cbl that are most directly involved in the ubiquitination process are the RING domain (17) and a linker region that lies between the RING domain and the N-terminal phosphotyrosine-binding (PTB) domain (also termed tyrosine kinase binding or TKB domain 2 ) (16, (18) (19) (20) . Deletion of all or part of these residues, as in the oncogenic v-Cbl and 70Z-Cbl, abolishes the ability of c-Cbl to mediate ubiquitination of growth factor receptors, generating dominant negative versions of c-Cbl (17) . Crystal structure analysis of the evolutionarily conserved N-terminal half of the c-Cbl molecule revealed that the PTB domain comprises three subdomains: a four-helix bundle, an EF-hand, and a divergent SH2 domain, all of which contribute residues necessary for the binding of phosphotyrosine-containing target proteins (21) .
The C-terminal-half of c-Cbl has a proline rich-region and several tyrosines which are phosphorylated in response to various stimuli, as well as a leucine zipper domain that mediates the formation of c-Cbl homodimers (22) . As yet, there is no evidence that the C-terminal domains play a role in the ubiquitination-related function of c-Cbl.
The ubiquitin system, in which the recruitment of ubiquitin-conjugating enzymes (E2) to specific proteins leads to their subsequent ubiquitination and degradation via the proteasome, selectively terminates the activity of many proteins in cells (23) (24) (25) (26) (27) . This pathway generally involves the sequential action of three types of molecules: a ubiquitin activating enzyme (E1), a 4 ubiquitin conjugating enzyme (E2) and a ubiquitin ligase (E3). We and others (10, 12, 16) have independently demonstrated that c-Cbl can function as a ubiquitin ligase (E3) for receptor tyrosine kinases such as the epidermal growth factor receptor (EGFR) and the platelet-derived growth factor receptor (PDGFR), thereby playing a key role in their down-regulation following ligand-binding. c-Cbl functions as an adaptor protein, binding the E2s with the RING and linker domains and positioning them in close proximity to the activated receptors that are bound to the c-Cbl PTB domain (10, 12, 16, 18) . It is not known if c-Cbl also plays a more active role in the actual transfer of ubiquitin from the E2 to the receptor.
Thus, it is becoming clear that the molecular mechanism by which c-Cbl exerts its negative regulation of RTKs involves both direct binding to the activated receptor via c-Cbl's PTB domain and the recruitment of the ubiquitin system via the RING finger. c-Cbl is however known to bind to numerous other proteins (20, 28) and, of particular interest here, it is also a negative regulator of non-receptor tyrosine kinases, particularly members of the Src family of tyrosine kinases (29, 30) .
The Src family of tyrosine kinases is involved in a variety of cellular signaling pathways, leading to the induction of DNA synthesis, cell proliferation and cytoskeletal reorganization (31) (32) (33) . Src tyrosine kinase activity is tightly regulated and its dysregulation leads to constitutive activation and cellular transformation. Src kinase activity is regulated by the phosphorylation/dephosphorylation of a specific tyrosine residue in the C-terminal tail (tyrosine 527 in avian c-Src), which binds intramolecularly to the SH2 domain, as well as via an interaction between the SH3 domain and the linker region that connects the SH2 and kinase domains (34, 35) . The dephosphorylation of tyrosine 527 leads to the release of the intramolecular interaction with the SH2 domain and the consequent activation of Src. Finally, recent studies have shown that Src kinase activity can also be down-regulated by ubiquitin-dependent degradation (38, 39) , but the possible role of c-Cbl in this process has not been explored. Given that Cbl is known to interact with Src (30, 40, 41) and is capable of recruiting the ubiquitin system to specific substrates (10, 12, 16) , we hypothesized that, like the RTKs, Src's interaction with c-Cbl may lead to its ubiquitination. In this report, we show that c-Cbl acts as an E3 for Src and that their interaction leads to the ubiquitination not only of active and c-Cbl Y371F were created by site-directed mutagenesis (Quick Change site-directed mutagenesis kit obtained from Stratagene) using pcDNA3.1-c-Cbl as template. All mutations were confirmed by sequencing and then subcloned into the pBluebacHis2 vector. Wild type avian-Src was subcloned into pVL1393 vector (Pharmingen). Standard procedures were used for the recombinant DNA manipulations (42, 43) . The myc-tagged c-Cbl mutants have been previously described (22) .
Production and purification of proteins
Sf-9 cells were transfected with c-Cbl and Src constructs according to the manufacturer's protocol (Pharmingen). Cells expressing c-Cbl and mutant Cbl proteins were washed twice with PBS and incubated in a buffer containing 0.5% IGEPAL CA-630 (Sigma, St.
Louis, MO), 20 mM Hepes, pH7.2, 50 mM NaF, 100 µM sodium vanadate, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 µg/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride and 20 mM MG132 for 30 min on ice. Lysates were centrifuged at 10,000xg for 30 min. The His-tagged proteins were purified from the clarified lysate by using nickel-nitrilotriacetic acid-agarose (Qiagen), according to the protocol supplied by the manufacturer. To obtain purified phosphorylated proteins, Sf-9 cells were treated with 0.1 mM of sodium vanadate as described elsewhere (44).
The purification of the phosphorylated-proteins was carried out as described above. To obtain cell extracts from NIH 3T3 cells expressing various avian Src constructs or Sf-9 cells expressing various recombinant avian Src proteins, cells were washed twice with PBS and lysed in a buffer containing 20 mM Hepes, pH 7.2, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM dithiothreitol, 25 µM MG132, and protease and phosphatase inhibitors as described above. Lysates were sonicated for two cycles of 30 sec and subsequently clarified by centrifugation at 10,000 x g for 30 min. E1 and Src were expressed in Sf9 cells, whereas GST-E2 (UbcH7) was expressed in E.
coli. Both E1 and E2 were purified as described elsewhere (16, 45) .
In vitro ubiquitination assay
The standard ubiquitination reaction mixture (50 µl) contained the 20 mM Hepes, pH7.2, 10 mM MgCl 2 , 1 mM ATP, 1 mM DTT, 30 mM creatine phosphate, 0.1 mg/ml creatine kinase, 25 µM MG132 (to inhibit the degradation of ubiquitinated proteins), 2.5 µg of GST-ubiquitin, 100-400 ng of purified c-Cbl or mutant Cbl protein and 20-1000 µg of cell extracts containing protease and phosphatase inhibitors. In some experiments, cell extracts were pretreated with the Src kinase inhibitor PP1 (Biomol) for 15 min before adding the ubiquitination reaction mixture.
The reaction was initiated by the addition of 2.5 µg GST-ubiquitin, incubated at 30 0 C for 1hr, and terminated by adding 5µl of 0.5 M EDTA. The ubiquitinated proteins in the reaction mixture were pulled down with GSH-sepharose. The GSH-sepharose beads were washed with 0.5% IGEPAL CA 630 (Sigma) in PBS three times, then boiled in 2 X SDS-PAGE buffer and the samples were electrophoresed on 8% Tris-glycine gels (Novex). Western blotting was performed using 1:1000 dilutions of the appropriate antibody and visualized by enhanced chemiluminescence (Amresham Pharmacia Biotech) according to the manufacturers instructions.
In vitro binding assay
The reaction mixture (50 µl) that were associated with the GST-UbcH7 were isolated using GSH-Sepharose beads. The beads were washed with the reaction buffer without ATP but including the protease inhibitors.
Immobilized proteins were electrophoresed and analyzed by Western blotting as described above. For some experiments, cell extracts were derived from Src-expressing Sf9 cells pretreated with PP1 for 15 min
Luciferase assay
A luciferase reporter gene construct containing the APRE promotor, cDNA encoding β-galactosidase and plasmids encoding v-Src and/or myc-tagged c-Cbl or mutant Cbl constructs were co-transfected into HEK 293 cells using the calcium-phosphate method as described elsewhere (16) . After 36 h, cell extracts were prepared and luciferase and β-galactosidase (a control for transfection efficiency) activities were measured as described previously (46) . We then asked whether the Src kinase activity was necessary for this c-Cbl-dependent ubiquitination event. We had detected no ubiquitination of Src K295M/Y527F, a Src molecule that is in the same "open" conformation as SrcY527F but is catalytically inactive (Fig. 1B), indicating that an open conformation is not sufficient for Src polyubiquitination, and that catalytic activity is required (Fig. 1B) . To further determine whether the c-Cbl-mediated ubiquitination of Src is kinase-dependent, we examined the effect of the Src kinase inhibitor PP1 on the Src ubiquitination (Fig. 1C) . Addition of PP1 to the assay inhibited the c-Cbl-dependent ubiquitination of SrcY527F in a dose-dependent manner. These results clearly showed that cCbl-mediated ubiquitination of active Src not only requires the c-Cbl RING finger, but is also dependent upon the kinase activity of Src.
We also failed to detect ubiquitination of SrcY416F/Y527F, in which the (Fig. 1D) indicating that phosphorylation of tyrosine 416 is not required for c-Cblmediated Src ubiquitination. In contrast, Src K295M/Y527F, which has entirely lost its kinase activity, failed to be ubiquitinated, even when present at high concentrations (data not shown).
These results confirmed that while the kinase activity of Src is required for the c-Cbl-dependent ubiquitination of Src, the phosphorylation of tyrosine 416 is not essential per se.
Active Src kinase also promotes the ubiquitination of c-Cbl
We then considered the possibility that c-Cbl itself could become ubiquitinated in the process, potentially leading to the degradation of both components of the Src/c-Cbl complex.
To address this question, we performed the same ubiquitination assay as described in Fig. 1, but immunoblotted the ubiquitinated proteins with anti-c-Cbl antibody. As shown in Fig. 2A , c-Cbl was extensively polyubiquitinated in the presence of constitutively active SrcY527F (lanes 10 and 14). In contrast, there was little or no detectable ubiquitination of c-Cbl when extracts from Src -/-or 3T3 cells (which express little endogenous Src, data not shown), or the catalytically inactive Src K295M were used in the assay ( Fig. 2A, lanes 2, 4 and 12 ). Low to moderate levels of ubiquitination of c-Cbl were seen in the presence of overexpressed c-Src, or Src Y416F/Y527F Src cell extracts. (Fig. 2A, lanes 6 and 8) . As previously observed for Src itself, the ubiquitination of c-Cbl required catalytically active Src ( Fig. 2A compare lanes 12 and14) , and was dramatically inhibited as the amount of Src Y527F was decreased (Fig. 2B, lanes 4-7) or as the Src kinase inhibitor PP1 was added (Fig. 2B, lanes 8-10) . Thus, the kinase activity of Src is required not only for its own, c-Cbl-dependent, ubiquitination (Fig. 1, A and B) but also for the ubiquitination of c-Cbl.
We previously showed that 70Z-Cbl, which lacks 17 residues within the linker and RING domain, fails to bind the ubiquitin conjugating enzyme UbcH7 or to mediate the ubiquitination of the EGF receptor (16) . We therefore predicted that the defective linker and RING domain of 70Z-Cbl would prevent its ubiquitination. As hypothesized, 70Z-Cbl was not 13 ubiquitinated (Fig. 2C, lanes 4 and 5) , although it binds to, and is tyrosine phosphorylated by Src as efficiently as c-Cbl (data not shown). Thus, the RING finger domain of c-Cbl is essential not only for the ubiquitination of the targeted protein (EGFR, PDGFR or, as shown here, Src) but also for c-Cbl auto-ubiquitination.
An active PTB domain of c-Cbl is not essential for the ubiquitination of Src
We have recently shown that the PTB domain of c-Cbl negatively regulates Src kinase activity following engagement of the vitronectin receptor (30) . Moreover, a point mutation (G306E) that inactivates the PTB domain of c-Cbl abrogates the ability of c-Cbl to promote the ligand-induced ubiquitination of the PDGFR (13) . Nevertheless, c-Cbl G306E still associates with the activated PDGFR via its C-terminus region, suggesting that the interaction of the PTB domain with the receptor somehow promotes the transfer of ubiquitin from UbcH7 to the receptor. We therefore examined the potential role of the PTB domain in c-Cbl-mediated Src ubiquitination. As shown in Fig. 3A , the G306E mutation did not impair, and possibly enhanced, the ability of c-Cbl to induce ubiquitination of Src (upper panel) or its own ubiquitination (lower panel).
To further assess which domains of c-Cbl were responsible for the molecular interaction leading to the c-Cbl-mediated ubiquitination of Src, we determined whether the C-terminal half of c-Cbl, which contains the Src-binding proline-rich region, was required for Src to be ubiquitinated. Removing the C-terminal half of c-Cbl markedly reduced the ability of c-Cbl to promote Src ubiquitination (Fig. 3B, compare lanes 3 and 5) . These findings suggest that the interaction between the SH3 domain of Src and the proline-rich region of c-Cbl is necessary for Src to fully induce c-Cbl's ubiquitin ligase activity, which is responsible in turn for the 14 ubiquitination of both proteins.
Phosphorylation of c-Cbl promotes its ubiquitination
To further test the role of c-Cbl as an E3 ligase we modified the in vitro ubiquitination assay by replacing the mammalian cell extracts with purified recombinant components of the ubiquitination system (Fig. 4) . We found that c-Cbl, but not 70Z-Cbl, was clearly ubiquitinated only when E1, E2 and Src were all present in this cell-free system (Fig. 4A, compare lanes 4 and   6) . These results strongly suggest that c-Cbl mediates its own ubiquitination.
Because Src and c-Cbl ubiquitination requires the presence of catalytically active Src, and c-Cbl is phosphorylated by Src, we hypothesized that phosphorylation of c-Cbl was necessary for its E3 ligase activity and its own ubiquitination. To test this, we phosphorylated cCbl and 70Z-Cbl as described in Experimental Procedures and performed the ubiquitination assay in the absence of Src kinase. As shown in Fig. 4B , c-Cbl and 70Z-Cbl proteins (Cbl-P, 70Z-Cbl-P) purified from pervanadate-treated cells were highly tyrosine phosphorylated. In contrast to the unphosphorylated protein, the phosphorylated c-Cbl was polyubiquitinated despite the absence of Src kinase in the assay (Fig. 4C, left panel, compare lanes 2 and 3) .
Neither the phosphorylated nor the unphosphorylated 70Z-Cbl proteins were ubiquitinated ( (Fig. 5B, right panel) . Thus, tyrosine 371 and/or its phosphorylation appears to be specifically required for recruiting the ubiquitin conjugating protein and/or for triggering the transfer of ubiquitin from UbcH7 to c-Cbl and Src.
Phosphorylated c-Cbl is an efficient ubiquitin ligase
To further confirm our interpretation of the above data, we tested the ubiquitin ligase activity of the prephosphorylated c-Cbl. In order to better observe the effect of c-Cbl phosphorylation, we used lysates from cells that overexpress Src Y416F/Y527F in the assay. As failed to induce any more ubiquitination than was seen in the lysate without exogenous c-Cbl (Fig. 5C, lane 2) , consistent with its previously described inactivity. These results indicate that the tyrosine phosphorylation of c-Cbl may be a trigger that activates its ubiquitin ligase activity.
Activation of Src leads to the dissociation of the c-Cbl/UbcH7 complex
To investigate whether c-Cbl binding to and/or dissociation from the UbcH7 was a phosphorylation-dependent event, we performed an in vitro binding assay (Fig. 6 ) in which recombinant c-Cbl was incubated with GST-UbcH7 in the presence or absence of Src and ATP.
To determine the role of Src kinase activity, ATP was omitted or the Src inhibitor PP1 was added. The GST-ubiquitin and any associated proteins were isolated using GSH-Sepharose and the compositions of the complexes were determined by Western blot. c-Cbl was found to bind GST-UbcH7 in absence of Src (Fig. 6, lane 3) , indicating that the UbcH7-c-Cbl interaction does not require that c-Cbl be phosphorylated. When both Src and ATP were present, the interaction between c-Cbl and UbcH7 was lost (Fig. 6, lane 4) , whereas the addition of Src in the absence of ATP (Fig. 6, lane 7) or inhibition of Src kinase activity by PP1 (Fig. 6, lanes 5 and 6) prevented the disruption of the c-Cbl-UbcH7 interaction. Most interestingly, the complex isolated from the assays where Src kinase activity was prevented by the addition of the kinase inhibitor or the omission of ATP also contained Src in addition to c-Cbl and UbcH7 (Fig. 7,   lanes 5, 6 and 7) . Thus, it appears that the phosphorylation of c-Cbl by Src is required for both the ubiquitination of Src and c-Cbl and for the dissociation of the tri-molecular complex.
One surprising result is the finding that much less Src bound to the c-Cbl-UbcH7 complex when ATP was omitted from the assay than when Src was inhibited by the higher concentration of the kinase inhibitor PP1. This could be due to the fact that some ATP is Ubiquitination and the consequent degradation of the ubiquitinated proteins by the proteasome or lysosomal pathways plays an important role in the control of numerous cellular processes, including signal transduction (23) (24) (25) (26) (27) . Ubiquitination involves the sequential action of three types of enzymes: first, the ubiquitin-activating enzyme (E1), second, the ubiquitinconjugating enzyme (E2) and finally the ubiquitin-protein ligase enzyme (E3) (25) . Of these three steps, the E3-mediated ligation step is the most diverse and specific, in that it is the E3s that provide both the specific motifs to recognize the substrate to be ubiquitinated and motifs that bind to specific E2s. It is generally accepted that there are two types of E3 proteins, HECT E3s, which contain a conserved HECT catalytic domain, and RING domain-containing proteins such as c-Cbl (17, 18, (50) (51) (52) (53) , which have no known catalytic activity but bring the ubiquitin conjugating enzymes in close proximity to the substrate, as demonstrated for c-Cbl (27) .
This functional model of c-Cbl's RING finger interacting with the ubiquitinconjugating enzyme UbcH7, thereby bringing it into close proximity with a substrate and leading to the substrate's ubiquitination, has been strongly supported by the recently reported structure of the c-Cbl PTB and RING domains co-crystallized with UbcH7 and a PTB-binding peptide derived from Zap70, a T-cell-specific nonreceptor tyrosine kinase (18) .
That study demonstrated that UbcH7 interacts closely with both the RING domain and the C-terminal region of the linker between the PTB and the RING domains, consistent with our previous report showing that C86 of UbcH7, the site of the ubiquitin thioester linkage, is on the opposite face of the molecule relative to the PTB domain of c-Cbl, suggests that the answers to these questions will prove to be important for our understanding. noted that tyrosine 371 is in a buried environment, where it is not easily accessible to tyrosine kinases and appears to play a crucial structural role in the linker-PTB interface. These authors suggest that mutating this residue would strongly affect the integrity of the linker-PTB interface and possibly lead to conformational changes that could prevent ubiquitination from occurring.
That this region participates in more than simply the ubiquitination machinery is also indicated by the recent report of Thien et al. (19) , who showed that deletion or mutation to alanine of tyrosine 371, which are more disruptive than the mutation to phenylalanine, are required for cCbl to be transforming. Our data, however, show that tyrosine phosphorylation of c-Cbl is required, but not sufficient if tyrosine 371 is mutated to phenylalanine, for the ubiquitination of Src and c-Cbl. Whether mutation of tyrosine 371 would prevent formation of the c-Cbl / UbcH7 complex, the recruitment of Src to the complex or the dissociation of the trimolecular complex
has not yet been determined. In conclusion, we interpret our results to show that c-Cbl is an E3 ubiquitin ligase for non-receptor tyrosine kinases such as Src as well as for RTKs, and that it participates in the down-regulation of Src tyrosine kinase by mediating its ubiquitination, subsequent to Src's activation.
FOOTNOTES
1 The abbreviations used are: RTK, receptor tyrosine kinase; PTB, phosphotyrosine binding; EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; GST, glutathione S-transferase; GSH, glutathione.
2 We prefer the term PTB, which indicates that it binds to phosphorylated tyrosine residues. The term TKB fails to confer that information and also suggests that this domain binds to all or only to tyrosine kinases. Furthermore, as shown here for Src, Cbl can bind to tyrosine kinases through domains other than the TKB. Immobilized proteins were subjected to SDS-polyacrylamide gel electrophoresis followed by Western blotting as indicated. 
